Status:
COMPLETED
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Lipodystrophy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
HIV lipoatrophy is a condition marked by fat loss; it occurs in many patients taking antiretroviral (ARV) therapy that includes nucleoside reverse transcriptase inhibitors (NRTIs). Lipoatrophy may be ...
Detailed Description
NRTIs are an important part of many ARV regimens used to treat HIV infected patients; however, the relationship between NRTI-induced mitochondrial dysfunction and lipoatrophy is still unclear and requ...
Eligibility Criteria
Inclusion
- Diagnosis of HIV lipoatrophy
- Receiving a stable stavudine- or zidovudine-containing ARV regimen
- HIV-1 RNA viral load less than 50 copies/ml
Exclusion
- Coagulopathies or other bleeding disorders
- Diabetes requiring medication
- Creatinine clearance less than 50 ml/min
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00119379
Start Date
April 1 2005
End Date
October 1 2008
Last Update
June 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106